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ABSTRACT
Complicated skin and soft-tissue infections (cSSTIs) are a signiﬁcant clinical problem, partially owing to
increasing resistance of infecting bacteria to current antibiotic therapies. Two case studies that illustrate
complications that can arise when treating cSSTIs are outlined, and methods that can be used to address
the problem and the ﬁnal treatment outcome are detailed. Although these are speciﬁc examples,
intolerance of and bacterial resistance to current antibacterial therapies are problems that are often seen
in the clinical setting and must be addressed appropriately. The use of new antibiotic agents is one
potential solution to these problems, and some of these agents are highlighted. Selecting the most
appropriate therapy for an infection is often crucial for patient welfare. This article presents some
potential approaches to the treatment of cSSTIs.
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INTRODUCTION
Skin and soft-tissue infections (SSTIs; also known
as skin and skin-structure infections, or SSSIs, in
the USA) are deﬁned as infections of the epider-
mis, dermis, or subcutaneous tissue. They are
among the most common human bacterial infec-
tions and are frequently observed in clinical
practice [1–3], accounting for c. 10% of hospital
admissions for infections in the USA [1]. It has
also been shown that the incidence of SSTIs in the
USA is increasing [1]. This rise in incidence has
been attributed to several factors, including
increasing population age, surgical wounds
related to more invasive surgery in the ageing
population, obesity, diabetes, peripheral vascular
disease and immunocompromised status [4].
SSTIs, particularly those caused by Staphylococ-
cus aureus, can lead to bloodstream infections,
which are often associated with the development
of metastatic foci of infection. Thus, bacterial
endocarditis and other infections, such as deep-
seated abscesses and ⁄ or osteomyelitis, are well-
known complications of S. aureus bacteraemia [5].
An increase in the incidence of S. aureus endocar-
ditis has been observed [6], which is probably
partly due to the increased incidence of SSTIs,
although the greater proportion is attributable to
catheter-related infections [7–9].
The pathogenesis of SSTIs usually involves
direct inoculation of pathogens through skin
punctures or catheter insertions, but can also be
associated with skin conditions such as eczema
and dermatitis [2]. However, infections can also
spread to the skin from deeper foci or distant sites
[1–3]. Occasionally, there is no obvious source.
Correctly diagnosing SSTIs, identifying the asso-
ciated organism and addressing the focus are
crucial for rapid treatment and resolution of
the infection, and can also indicate appropriate
treatment regimens.
IDENTIFICATION, CLASSIFICATION
AND TREATMENT OF SKIN AND
SOFT-TISSUE INFECTIONS
SSTIs are primarily diagnosed through clinical
examination, which is combined with sample
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culture identiﬁcation and sensitivity testing to
provide a deﬁnitive diagnosis [10]. Identiﬁcation
of the causative organism will also guide the
choice of antibiotic therapy and can help to
establish the prognosis for the infection [2]. Once
diagnosed, SSTIs can be designated as one of
four classes according to the severity of infection
and the presence of systemic symptoms and
co-morbidities (Table 1). Uncomplicated SSTIs
are usually designated as class 1, whereas
complicated SSTIs (cSSTIs) are designated as
classes 2–4 on the basis of additional diagnostic
factors [4]. Examples of cSSTIs include infected
ulcer with associated cellulitis, necrotising fasci-
itis and surgical site infections (Table 2).
Because most cSSTIs involve deep soft tissues
or complicating factors, initial hospitalisation is
often required to perform surgery and adminis-
ter systemic antimicrobial therapy [4]. Empirical
therapy with broad-spectrum antibiotic coverage
usually follows diagnosis of a cSSTI; the therapy
is determined according to knowledge of the
most likely infecting pathogen(s) and local
susceptibility patterns, together with patient
factors such as age, renal and hepatic function,
and previous therapy. Broad-spectrum oral
antibiotics, such as amoxicillin–clavulanic acid,
clindamycin, quinolones and linezolid, are
frequently used for the treatment of uncompli-
cated infections; intravenous antibiotics, such as
b-lactams (sometimes with b-lactamase inhibi-
tors), broad-spectrum cephalosporins, carbape-
nem and linezolid, are generally used for more
serious infections [2,4]. Choosing the correct
empirical therapy following diagnosis is crucial
in providing the best early care and to decrease
the potential morbidity and mortality associated
with incorrect treatment of SSTIs [11].
Most cSSTIs are caused by Gram-positive
bacteria, primarily S. aureus and group A strep-
tococci; in addition, enterococci and various
Gram-negative bacteria and anaerobes are found
in mixed infections. Indeed, many bacteria are
capable of causing these infections [12]. Several
antibiotic classes and agents are frequently used
to treat conﬁrmed or likely Gram-positive cSSTIs;
these can include b-lactams, glycopeptides, oxa-
zolidinones and clindamycin [4]. However, the
decreasing susceptibility of some microorganisms
(e.g., S aureus [13–15]) to these agents is a
signiﬁcant problem in treating SSTIs [16]; this
problem has been further highlighted by a recent
report demonstrating that invasive methicillin-
resistant S. aureus (MRSA) infections in the USA
are not only an increasing problem in hospital
settings, but are also a signiﬁcant problem in
community-acquired infections [17,18]. In addi-
tion, the frequent need for appropriate surgical
drainage and ⁄ or debridement must not be over-
looked in treating cSSTIs.
CURRENT CHALLENGES IN THE
TREATMENT OF COMPLICATED
SKIN AND SOFT-TISSUE
INFECTIONS
Although many cases of SSTIs can be success-
fully treated using empirical antimicrobial ther-
apy, the increasing prevalence of antibiotic
resistance among some bacterial strains, partic-
ularly S. aureus, means that new treatment
options must be sought [19,20]. In addition to
the decreasing efﬁcacy of antibiotics against the
most resistant bacterial strains, the potential
toxicity of many antibiotics is of clinical
Table 1. Classiﬁcation of skin and soft-tissue infections
[4]
Class
Clinical presentation of
patient with skin infection
Class 1 Localised infection,
no signs or symptoms
of systemic toxicity;
afebrile and healthy,
other than cellulitis
Class 2 Febrile and ill-appearing
Class 3 Toxic appearance or at least
one unstable co-morbidity
Class 4 Sepsis syndrome or
life-threatening infection
Table 2. Common complicated skin and soft-tissue infec-
tions
Secondary infections of diseased skin
Acute wound infections (traumatic, bite-related,
post-operative)
Chronic wound infections (diabetic foot infections,
venous stasis ulcers, pressure sores)
Perianal cellulitis with or without abscess
Deeper soft-tissue infections, or those that require
surgical intervention
Infected ulcers, burns, major abscesses, and
superﬁcial infections or abscesses with a high risk
of an anaerobic or Gram-negative pathogen
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concern. For example, treatment with vancomy-
cin can lead to potentially serious disorders
such as nephrotoxicity [21], and treatment with
quinupristin–dalfopristin is also problematic
because of unfavourable adverse event proﬁles
and high cost [22]. Therefore, new antibiotic
classes without, or with minimal, potential for
bacterial resistance, in addition to low-toxicity
proﬁles, are needed for the treatment of serious
bacterial infections.
However, the need for surgical intervention,
particularly in more complicated cases, is ever
present [10]. In a recent observational study
concerning abscesses caused by community-asso-
ciated S. aureus strains [23]—which are probably
more virulent and invasive because of additional
toxins, e.g., Panton–Valentine leukocidin—the
authors concluded that most simple skin
abscesses, even when caused by MRSA, can be
cured with adequate drainage alone, and that
drainage was more important than the initial
choice of antibiotic in these cases. Thus, the
administration of appropriate surgical care is
critically important.
Two case studies from Cubist Pharmaceuticals’
database of clinical experience illustrate some of
these challenges in the clinical setting and
provide examples of how these challenges can be
addressed.
ULCERATION AND CELLULITIS
Cellulitis is an acute, spreading skin infection
that penetrates the subcutaneous tissue layer. It
can occur anywhere on the body [24] and is
usually a complication of a wound or ulcer;
oedema has also been shown to predispose
patients to developing cellulitis [25]. Cellulitis
of the skin and some subcutaneous tissues has
been shown to account for a signiﬁcant number
of medical visits in both the USA and the UK;
2.2% of visits to a physician in the USA [26] and
158 medical visits per 10 000 person-years in the
UK [27] have been attributed to cellulitis.
Numerous factors have been shown to predis-
pose patients to developing cellulitis, including
skin trauma and underlying skin lesions,
venous ⁄ lymphatic compromise and a history of
cellulitis [24,25].
The causative pathogens of cellulitis vary
according to the site of infection, but are usually
group A b-haemolytic streptococci, or S. aureus
[25]. However, cultures from aspirates and
lesions do not always reveal the causative
organism(s) and, therefore, many diagnoses are
based on the clinical presentation and morphol-
ogy of the lesion [25], with the most appropriate
empirical treatment being decided accordingly,
and modiﬁed according to the response of the
infection.
CASE STUDY: INFECTED LEG ULCER
Background
A 48-year-old female with peripheral vascular
disease, arterial insufﬁciency and occlusion, and a
history of recurrent leg ulcer infections, had
undergone an aorto–bifemoral bypass. The
patient presented with extreme pain and swelling
in the left ankle and was admitted for treatment.
Exudates from the ulcer yielded MRSA and
Enterobacter spp., which were identiﬁed by
day 3. Previous exposure to vancomycin had
resulted in signiﬁcant renal insufﬁciency and
eosinophilia; thus, vancomycin could not be used
to treat the patient, and the decision was made on
day 3 to initiate treatment with daptomycin plus
ceftriaxone.
Treatment
After initiation of intravenous daptomycin
4 mg ⁄ kg once-daily with intravenous ceftriaxone
2 g ⁄day, the infection was monitored routinely.
Less slough tissue was noted in the wound by
day 5, and the wound appeared to be healing
by day 7 (Fig. 1). Although antibiotic therapy
was disrupted by the patient for 3 days and was
recommenced on day 10, there was steady
improvement during the course of the treat-
ment. Following recommencement of antibiotic
therapy on day 10, further wound healing was
observed at day 12 and resolution of the infec-
tion occurred on day 14, when daptomycin and
ceftriaxone administration was discontinued
(Fig. 1).
Assessment
In this case, the previous history of side-effects
from vancomycin was a signiﬁcant factor in decid-
ing the appropriate therapy. Current treatment
guidelines for many countries (e.g., Australia [22]
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and the UK [28,29]) indicate that MRSA infection
should be treated with vancomycin, but this was
contraindicated in the case of this patient. Vanco-
mycin therapy is associated with low rates of
nephrotoxicity, which has been conﬁrmed since
the ﬁrst clinical use of this drug [21], and the
patient’s renal function must be monitored during
treatment with vancomycin to address any neph-
rotoxicities that may arise. However, the reported
rates of nephrotoxicity associated with vancomy-
cin vary signiﬁcantly, and it has been demon-
strated that the risk is increased if vancomycin is
co-administered with aminoglycosides or when
trough levels are high [30]. In addition to the
potential for nephrotoxicity, vancomycin is not
metabolised, and 90% of the infused drug is
cleared through glomerular ﬁltration and excretion
into the urine; thus, dosage modiﬁcation is neces-
sary in patients with renal insufﬁciencies [31].
Because vancomycin therapy was not an option
for this patient, daptomycin was chosen as the
most appropriate agent for treating the infection.
Daptomycin therapy resulted in signiﬁcant
improvements in the infection and wound healing
within 2 weeks of initiating therapy, and com-
plete resolution of the infection when the patient
was seen at day 21 (Fig. 1). No complications
resulting from ceftriaxone therapy for treatment
of the Enterobacter spp. were observed, and
ceftriaxone treatment resulted in clearance of the
infection and resolution by day 21. Although this
Gram-negative organism was recovered from the
infection, it was probably a secondary pathogen,
because it rarely causes skin infection by itself. In
addition, this co-pathogen was probably not an
extended-spectrum b-lactamase producer, or else
it would have been resistant to the ceftriaxone.
COMPLICATIONS ASSOCIATED
WITH DIABETES
Because of the associated peripheral neuropathy,
ulceration of the feet is a frequent problem in
diabetic patients, and infections of foot ulcers in
these patients can be limb- and life-threatening
[32]. Diabetic foot ulcers typically occur as a result
of factors such as puncture wounds, poorly ﬁtting
shoes or the presence of foreign bodies, which
exacerbate the underlying neurological or neuro-
vascular pathologies [32].
Delayed wound healing in diabetic foot ulcers
occurs frequently because of impaired sensation
Day 5 
Day 21 
Day 12 
Fig. 1. Infected leg ulcer. The patient presented with an
infected leg ulcer, the cause of which, methicillin-resistant
Staphylococcus aureus, was identiﬁed on day 3. Daptomycin
therapy was commenced on day 3, and less slough tissue
was observed on day 5. Although the treatment was
interrupted by the patient between days 7 and 10, recom-
mencement of treatment on day 10 led to noticeable
wound healing by day 12. Antibiotic therapy was stopped
on day 14, and complete healing of the wound had
occurred by day 21.
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resulting in a lack of protection and weight off-
loading of the diseased tissues. In those with
more advanced disease, this situation is further
compromised by impaired peripheral circulation,
altered leukocyte function, a disturbed balance of
cytokines and proteases, and chronic hypergly-
caemia [32]. After an infection is established, it
can spread rapidly and lead to complications such
as sepsis and osteomyelitis, and the risk of
amputation and mortality is increased [33]. It is
estimated that 40–60% of all non-traumatic ampu-
tations involve diabetic patients, and more than
85% of those are necessitated by diabetic foot
ulcers [34], which account for more hospitalisa-
tions than any other complication of diabetes.
Overall, the estimated prevalence of foot ulcers
among diabetics is c. 3–8% [34], and it is a
signiﬁcant problem in the management and
treatment of SSTIs.
Diabetic foot ulcers, which occur more fre-
quently in men than in women, and also more
frequently in patients aged ‡60 years, can occur in
patients with either type 1 or type 2 diabetes [32].
Management of the disease incorporates clearance
of the infecting pathogens and pressure relief, as
well as clearing and debridement of the infected
area if required. Diabetic foot ulcers are often
polymicrobial [35] and can be caused by numer-
ous Gram-positive and Gram-negative microbes
(both aerobic and anaerobic). Thus, they may
require complex treatment strategies involving
administration of two or more antimicrobials as
well as other therapy for the control of the
diabetic condition itself.
CASE STUDY: INFECTED DIABETIC
FOOT
Background
A 63-year-old female with type 2 diabetes pre-
sented with an ulcer on the tip of the fourth toe of
the left foot that had been present for c. 7 weeks,
with increased reddening and swelling during the
2–3 days before presentation. The patient had
severe diabetic polyneuropathy, obesity (body
mass index 32.8 kg ⁄m2), hypertension and
dyslipidaemia, and had previously had an ampu-
tation due to osteomyelitis, but had no history of
coronary artery disease, cardiovascular disease or
peripheral arterial disease. Following initial
assessment, the patient was referred to a
diabetologist with a diagnosis of non-healing foot
ulcer. Initial debridement was performed, and a
culture yielded methicillin-susceptible S. aureus
and group B b-haemolytic streptococci, sensitive
to clindamycin. Rapid progression of the infection
had occurred by the second visit 4 days later, and
led to hospital admission. At that time, the infec-
tion had spread to the complete forefoot and to
the depth of the bone in the wound centre (Fig. 2).
The patient’s medication consisted of normal
insulin (14–14–14 IU ⁄day) and basal insulin
(12–0–0–12 IU ⁄day) to control the diabetes, and
clindamycin (300 mg four-times-daily), which
she had received for 7 weeks. Treatment upon
admission comprised wound debridement with
removal of all necrotic tissue and infected bone,
local disinfection of the wound with polyhexa-
nide-soaked gauze, and removal of pressure from
the infected area by complete bed rest. In addi-
tion, the patient received low molecular weight
heparin and intensive insulin therapy. The anti-
biotic coverage against Gram-negative anaerobes
was provided by clindamycin. Treatment was
initiated with amoxicillin–clavulanic acid (1.2 g
three-times-daily), but was changed to vanco-
mycin 1 g ⁄day after 2 days on the basis of the
results of a resistogram. The patient also received
metronidazole (500 mg three-times-daily). The
plan was to amputate the toe, with wound closure
after complete control of the infection.
Treatment
After 5 days of treatment with vancomycin,
clinical signs of regression of the infection were
insufﬁcient; there was a persistent putrid secre-
tion and the level of C-reactive protein was not
normalised (26.2 mg ⁄L) (Fig. 2a). Antibiotic
therapy was thus changed to daptomycin
(6 mg ⁄kg). After 2 days of therapy, the putrid
secretion had cleared, there was regression of
reddening with persistent swelling of the toe and
the C-reactive protein was normalised (5 mg ⁄L)
(Fig. 2b). Amputation of the fourth toe was
performed on day 10 after admission (day 3 of
therapy with daptomycin), and this was followed
by uncomplicated primary wound healing.
Daptomycin was discontinued after 7 days
(Fig. 2c).
Although the S. aureus isolates from the ulcer
were classiﬁed as susceptible to vancomycin
treatment on the basis of results of the microbial
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susceptibility tests, treatment with vancomycin
was ineffective in clearing the infection. Treat-
ment with daptomycin led to a rapid resolution of
the infection, allowing the planned surgery to be
undertaken.
Assessment: empirical therapy and vancomycin
MIC creep
As can be seen from this case, appropriate
empirical therapy is important because adminis-
tration of inappropriate agents can have signiﬁ-
cant consequences for resolution of the infection.
For example, it has been shown that inappropri-
ate or delayed initial therapy for bloodstream
infections is associated with an increased length
of hospital stay and increased mortality [11,36,37].
Although bacterial isolates might be susceptible
to vancomycin in vitro, this does not always
predict the susceptibility of the infection in the
patient [38]. Aside from the issue of strain
susceptibility, vancomycin has a less than ideal
pharmacokinetic–pharmacodynamic proﬁle;
potentially, vancomycin’s low concentrations at
the infection site and slow bactericidal activity
may have contributed to the failure of vancomy-
cin therapy in this case [39,40].
The MIC is used to determine bacterial sus-
ceptibility to a chosen antibiotic [41]. However,
with regard to S. aureus, the classiﬁcation of
susceptibility to vancomycin (S. aureus is deemed
susceptible to vancomycin if concentrations
£2 mg ⁄L inhibit growth in vitro) may not accu-
rately predict efﬁcacy in vivo [38]. For example,
recent studies have shown that infections due to
MRSA isolates with vancomycin MIC values of
£0.5 mg ⁄L were associated with a 55.6% treat-
ment success rate with vancomycin, whereas
those with MIC values of 1–2 mg ⁄L were asso-
ciated with a 9.5% treatment success rate [42].
These results demonstrate that, although the
S. aureus isolates were initially deemed suscepti-
ble to vancomycin, the overall clinical response
(a)
(b)
(c)
Fig. 2. Infected diabetic foot. The patient presented with
an infected ulcer on the tip of the fourth toe of the left foot.
The patient was hospitalised following assessment by a
diabetologist, and initial wound debridement and cultures
revealed methicillin-susceptible Staphylococcus aureus and
group B b-haemolytic streptococci. Initial antibiotic treat-
ment of the ulcer had no effect on the infection, and further
treatment with vancomycin also resulted in insufﬁcient
regression of the infection (a). Treatment with daptomycin
was commenced and resulted in reduction in the swelling
and absence of putrid secretions after 2 days (b). Ampu-
tation of the fourth toe was performed on day 10 after
admission (day 3 of therapy with daptomycin), and
uncomplicated primary wound healing occurred after
amputation; daptomycin was discontinued after 7 days (c).
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indicated otherwise. Vancomycin MIC creep (the
gradual reduction in in-vitro susceptibility of
S. aureus to vancomycin) has been observed in
several hospitals [43], although other studies
have indicated that there has been no decrease
in susceptibility over recent years [38]. Undoubt-
edly, the clinical efﬁcacy of vancomycin against
S. aureus strains is increasingly being questioned.
Underlying the debate are fundamental clinical
issues with respect to the accurate laboratory
identiﬁcation of vancomycin-intermediate
S. aureus and heteroresistant vancomycin-inter-
mediate S. aureus strains, the potential need for a
further reduction in vancomycin breakpoints, the
presence of bacterial tolerance and the appropri-
ate vancomycin dosing regimen—issues that
must be addressed to provide the best possible
care for patients [44].
CONCLUSION
The term SSTI covers several infections that can
be caused by a variety of organisms [2]. Although
uncomplicated SSTIs can usually be treated using
oral antibiotics on an outpatient basis [4], most
cSSTIs involve deep soft tissues or have compli-
cating factors and, therefore, initial hospitalisation
is often required to perform surgery and admin-
ister systemic antimicrobial therapy [4]. Broad-
spectrum antibiotics are the mainstay of many
cSSTI treatment regimens [2], but the efﬁcacy and
target range of these agents are constantly
decreasing as a result of the development of
resistance by microorganisms [16], in particular
by S. aureus [13–15]. New agents with favourable
safety and tolerability proﬁles are needed to
overcome this problem.
Daptomycin, a cyclic lipopeptide, is a particu-
larly useful addition to currently available agents
for treating cSSTIs, particularly those caused by
either methicillin-susceptible S. aureus or MRSA.
In clinical trials, daptomycin was equivalent to
standard-of-care treatment regimens such as
vancomycin and penicillinase-resistant penicillins
[45]. In addition to daptomycin, tigecycline (a
broad-spectrum glycylcycline antibiotic that is
effective against both Gram-positive and Gram-
negative pathogens [46]) is also approved for the
treatment of cSSTIs, and dalbavancin (a lipogly-
copeptide antibiotic that has shown efﬁcacy
against Gram-positive pathogens such as
S. aureus [47]) is expected to be approved for the
treatment of cSSTIs in 2008 in both the USA and
the EU. These new antibiotics are potentially
alternative agents for tackling the problem of
antibiotic resistance in SSTIs and other bacterial
infections [45,47,48].
Although surgical intervention is one of the
central strategies in the management of cSSTIs
[49], appropriate empirical antibiotic therapy at
an early stage is important to provide the best
possible patient care and to decrease the overall
risk of mortality due to cSSTIs. It has been
demonstrated that incorrect empirical therapy is
associated with a longer hospital stay, a higher
overall mortality rate, and a higher risk of
infection-related mortality [11]. However,
in-vitro susceptibility does not always mean that
the organism will be susceptible in vivo [38];
thus, constant monitoring of infections is
required to ensure that the administered therapy
is working as envisaged. As resistance to anti-
biotics such as vancomycin and b-lactam antibi-
otics continues to increase, new antibiotic agents
will be central in providing the best possible
care for patients and tackling the most problem-
atic infections. Prompt clinical assessment and
microbiological sampling is the key to a precise
diagnosis of cSSTIs [11], and new agents will
provide further options for treating these infec-
tions and the complications that arise from
them.
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